ARCT (Arcturus Therapeutics Holdings Inc.) PDUFA Date

Jul 20, 2026

Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

Arcturus Therapeutics Holdings Inc. has announced its participation in the Canaccord Genuity 46th Annual Growth Conference. The event will take place on August 11, 2026, in Boston, Massachusetts, where the company will engage in a fireside chat. This presentation underscores Arcturus's commitment to advancing its messenger RNA therapeutics.

Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis

Arcturus Therapeutics has announced a strategic collaboration with Thermo Fisher Scientific to advance its investigational therapy ARCT-032 for cystic fibrosis. This partnership aims to leverage Thermo Fisher's expertise in biopharmaceutical development to enhance the therapeutic potential of ARCT-032. The collaboration is expected to provide significant advancements in treatment options for cystic fibrosis patients.

May 26, 2026

▲ +6.2%on this news

Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

Arcturus Therapeutics Holdings Inc. has announced its participation in the 2026 Jefferies Global Healthcare Conference. The company, known for its focus on messenger RNA medicines, aims to showcase its developments in therapeutics for liver and respiratory rare diseases. This presentation reflects Arcturus's commitment to engaging with the healthcare investment community.

May 7, 2026

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics has reported its financial results for the first quarter of 2026, along with updates on its pipeline. The announcement highlights the company's ongoing efforts in advancing its therapeutic developments. However, specific details regarding financial performance and pipeline progress were not disclosed in the article.

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026

Arcturus Therapeutics Holdings Inc. will announce its financial results for Q1 2026 on May 7, 2026, after market close. A conference call and webcast will follow at 4:30 PM ET on the same day. The company specializes in mRNA medicines targeting rare liver and respiratory diseases.

Mar 5, 2026

Arcturus Therapeutics to Attend Upcoming March 2026 Investor Conference

Arcturus Therapeutics Holdings Inc. will participate in the Leerink Partners 2026 Global Healthcare Conference in Miami, Florida. The company specializes in messenger RNA medicines aimed at treating rare diseases. Arcturus has a robust pipeline, including candidates for cystic fibrosis and ornithine transcarbamylase deficiency, and has developed the world's first self-amplifying mRNA COVID vaccine.

Mar 4, 2026

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress

Arcturus Therapeutics reported its financial results for Q4 and fiscal year 2025, highlighting a net loss of $65.8 million. The company announced that its ARCT-032 program is permitted to proceed into a 12-week Phase 2 study, with dosing expected to begin in the first half of 2026. Despite revenue declines, Arcturus has extended its cash runway into Q2 2028, indicating a strategic focus on its rare disease therapeutic portfolio.

Feb 18, 2026

Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026

Arcturus Therapeutics Holdings Inc. will announce its financial results for Q4 and fiscal year 2025 on March 3, 2026. The company will also hold a conference call and webcast at 4:30 p.m. ET on the same day. Arcturus is known for its mRNA medicines and has a diverse pipeline targeting rare diseases and infectious diseases.

Jan 9, 2026

Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Arcturus Therapeutics Holdings Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Joseph Payne will discuss the company's advancements in mRNA medicines and vaccines, highlighting their innovative technologies and ongoing collaborations. Arcturus focuses on therapeutics for rare diseases and infectious diseases.

Nov 10, 2025

Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress Encouraging CF interim Phase 2 data support continued and expanded trial design 12-week safety and preliminary efficacy study in u

Arcturus Therapeutics announced its financial results for Q3 2025, highlighting encouraging interim data for its cystic fibrosis treatment, ARCT-032. The company plans to initiate a safety and efficacy study for ARCT-032 in early 2026. Despite these positive developments, Arcturus faces challenges including a delay in the U.S. BLA filing for KOSTAIVE and a reported increase in net loss compared to the previous year, alongside significant revenue declines due to reduced collaboration activities. The firm aims to extend its cash runway through planned cost reductions.

Aug 11, 2025

Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress Cystic fibrosis (ARCT-032) Phase 2 interim data from first nine participants to be presented in September Cystic fibrosis Phase 2

Arcturus Therapeutics announced its second quarter financial results and pipeline progress, highlighting an expected presentation of Phase 2 interim data for its cystic fibrosis program in September. The company reported a net loss of approximately $9.2 million for the second quarter of 2025, which, while an improvement from the previous year, indicates ongoing financial challenges. Despite declines in revenue, the firm has a strong cash position, ensuring operational sustainability into 2028. The existing trials for ARCT-810 and other programs continue as Arcturus navigates its strategic collaborations.

Jun 30, 2025

Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program ARCT-810 significantly and consistently reduces biomarker glutamine to levels within nor

Arcturus Therapeutics announced positive interim Phase 2 results for ARCT-810, an mRNA therapeutic for Ornithine Transcarbamylase (OTC) deficiency. The treatment significantly reduced glutamine levels to normal and maintained stable ammonia levels. The data, including improvements in ureagenesis function, suggest that multiple doses are safe and well tolerated. With these encouraging findings, Arcturus aims to progress towards pivotal study designs for the treatment of this rare metabolic disorder.

Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress Prioritization of mRNA therapeutics pipeline extends cash runway into 2028 ARCT-032 (CF) Phase 2 interim data from first two cohor

Arcturus Therapeutics has provided a financial update for the first quarter of 2025, reporting a cash runway extension into 2028 and highlighting clinical advancements in its mRNA therapeutics pipeline, particularly for cystic fibrosis and ornithine transcarbamylase deficiency. Despite a revenue decrease compared to the prior year, the company has successfully managed its expenses, resulting in a reduced net loss for the quarter. They also noted an initial milestone payment from their partnership with CSL, reflecting positive developments in their collaborations and financial management.

Mar 6, 2025

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress Phase 2 interim data for ARCT-032 (CF) & ARCT-810 (OTCD) on track for Q2 2025 Meiji Seika Pharma and ARCALIS rece

Arcturus Therapeutics has provided its financial update for Q4 and fiscal year 2024, reporting a decrease in revenue and net losses. Despite these financial challenges, the company announced progress in its clinical pipeline, specifically with ARCT-032 and ARCT-810, expecting interim Phase 2 data in Q2 2025. KOSTAIVE, their self-amplifying mRNA COVID vaccine, has received approvals for manufacturing in Europe and Japan, which could enhance its commercialization efforts. The company is maintaining a strong cash position, expected to last until the end of Q1 2027.

Aug 5, 2024

Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress IND submitted for Phase 2 trial of ARCT-032 targeting cystic fibrosis (CF) ARCT-810 (OTC deficiency) Phase 2 interim data on trac

Arcturus Therapeutics provided a financial update for Q2 2024, reporting substantial revenue growth to $49.9 million, primarily through strategic alliances. The company is positioned to launch its first commercial product, Kostaive, in Japan later this year. Clinical development for its mRNA therapeutics pipeline, especially ARCT-032 and ARCT-810, is underway, with meaningful safety data collected. However, the company still faced a net loss of $17.2 million during the quarter, though this was an improvement from the previous year.

Jun 20, 2024

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors Previously Chief Scientific Advisor for Operation Warp Speed, advised U.S. President's Council of Advisors on Science and Technology, member of A

Arcturus Therapeutics has appointed Moncef Slaoui, Ph.D., to its Board of Directors. Slaoui is noted for his previous role as Chief Scientific Advisor for Operation Warp Speed, contributing to rapid vaccine development. His extensive experience in pharmaceutical R&D and significant leadership roles in other biotech firms may positively influence Arcturus' mRNA vaccine and therapeutic pipeline. This appointment is seen as a strategic move as the company aims to advance its innovative technologies.

May 8, 2024

Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress Commercial manufacture of Kostaive on track for delivery of initial 4 million doses in Q3 Kostaive European Marketing Authorizatio

Arcturus Therapeutics reported its financial results for Q1 2024, demonstrating a net loss of $26.8 million compared to a profit in the same quarter last year. However, the company is on track to produce its COVID-19 vaccine Kostaive, with initial deliveries planned for Q3. They anticipate further clinical updates for key programs in July and have a strong cash position to support operations for at least the next three years. Additionally, Arcturus is engaging JP Morgan to monetize its joint venture in Japan, reflecting a proactive approach to financial management.

Mar 7, 2024

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress Kostaive anticipated to launch in Japan this year ARCT-032 remains on track for Phase 1b interim data in Q2 ARCT-

Arcturus Therapeutics provided its financial update for Q4 and FY 2023, highlighting the launch of Kostaive in Japan and the progress of ARCT-032 toward Phase 1b data and ARCT-810 toward Phase 2 interim data. The company's cash runway has been extended to Q1 2027 due to disciplined cost management. Despite the positive developments, Arcturus reported a net loss and a decline in revenue compared to the previous year. The company’s advancements in mRNA technology and vaccine programs reflect its ongoing commitment to addressing infectious diseases and rare diseases.

Nov 14, 2023

▲ +9.5%on this news· ran to +41% by day 3

Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress Expected cash runway extended to the end of 2026 $35 million milestone achieved under CSL collaboration ARCT-154 remains on track

Arcturus Therapeutics has announced a positive update for the third quarter of 2023, reporting an extended cash runway until the end of 2026 and successful milestones including the upcoming approval of the ARCT-154 COVID vaccine. They achieved their enrollment target for a bivalent vaccine trial and initiated a study for ARCT-032, an inhaled treatment for cystic fibrosis. However, the company also reported a net loss of $16.2 million for the quarter, and their total operating expenses have seen an increase from the previous year.

Sep 26, 2023

Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis CF Foundation Increases Financial Commitment to ~$25

Arcturus Therapeutics has extended its partnership with the Cystic Fibrosis Foundation, which has increased its financial commitment to about $25 million for the advancement of ARCT-032, a novel mRNA therapeutic. This therapy aims to address the root cause of cystic fibrosis by delivering functional CFTR protein to the lungs. The program is progressing through clinical studies, with a Phase 1 study already completed in healthy volunteers. The agreement reflects ongoing collaboration since 2017, aimed at enhancing treatment options for cystic fibrosis patients.

Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government LUNAR-FLU collaboration with CSL Seqirus achieves additional $17.5 million development

Arcturus Therapeutics announced that its joint venture ARCALIS has been awarded $115 million in grants from the Japanese government to support mRNA vaccine production. This funding will be utilized for constructing a new factory in Minamisoma City, Japan, aimed at cGMP manufacturing of mRNA products. Additionally, the LUNAR-FLU program, developed in collaboration with CSL Seqirus, has reached a $17.5 million milestone aimed at advancing flu vaccine development. This progress underscores the strategic partnerships and advancements within Arcturus' initiatives in mRNA technology.

Aug 7, 2023

Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress ARCT-154 Phase 3 COVID-19 booster trial achieved primary endpoint demonstrating strong immune response and favorable safety profi

Arcturus Therapeutics reported its second quarter 2023 financial results, highlighting progress in its clinical pipeline, particularly with the ARCT-154 COVID-19 booster trial, which achieved its primary endpoint. The company received FDA Fast Track and Rare Pediatric Disease Designations for ARCT-810, while ARCT-032 has been approved for Phase 1b studies in cystic fibrosis patients. However, revenue fell significantly in comparison to 2022 due to the termination of prior agreements, leading to an increased net loss for the quarter.

June 30 , 2023 Name of Company: Meiji Holdings Co., Ltd. Name of Representative: Kazuo Kawamura, CEO, President and Representative Director Code Number: 2269, Prime Market, Tokyo Stock Exchange Additional Application for

Meiji Holdings Co., Ltd. announced that its subsidiary, Meiji Seika Pharma Co., Ltd., has submitted an additional application for a booster dose of ARCT-154, a self-amplifying mRNA vaccine against COVID-19, in adults in Japan. The application is based on favorable results from a Phase III clinical trial. The vaccine aims to provide a strong immune response and potentially extended duration of protection while utilizing lower doses. The company is also working on establishing manufacturing capabilities for the mRNA vaccine in Japan and hopes to supply ARCT-154 following regulatory approval.

May 9, 2023

Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress New Drug Application (NDA) for ARCT-154, a next generation COVID-19 vaccine, was submitted in Japan, leading to potential approval

Arcturus Therapeutics reported its financial results for Q1 2023, highlighting a significant milestone with the NDA submission for its next-generation COVID-19 vaccine, ARCT-154, in Japan, which could lead to approval later this year. The company received $23.6 million for its manufacturing and supply of ARCT-154 and reported total revenues of $80.3 million for the quarter, a notable increase from the previous year's $5.2 million. Despite increased operating expenses and R&D costs, the company's cash runway extends through early 2026, bolstering its financial outlook.

Apr 28, 2023

DATED APRIL 28, 2023

Meiji Seika Pharma Co., Ltd., a subsidiary of Meiji Holdings, has submitted a New Drug Application for ARCT-154, a next-generation mRNA vaccine targeting COVID-19 in adults in Japan. The submission is based on favorable results from a Phase III trial in Vietnam that involved over 16,000 participants, demonstrating effective prevention of the virus. Additionally, Meiji is collaborating with ARCALIS, Inc. to establish a manufacturing facility in Fukushima Prefecture. The timeline for supply post-approval remains uncertain regarding its financial impact.

Mar 28, 2023

Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress $200 million upfront payment received in December 2022 from CSL collaboration Achieved $90 million in development milestones in M

Arcturus Therapeutics reported a positive financial update for the fourth quarter of 2022, including significant collaborations and developments in their pipeline. They received a $200 million upfront payment from CSL and achieved $90 million in milestones following their collaboration. The company also completed full enrollment for its ARCT-154 Phase 3 COVID-19 booster trial ahead of schedule. Financially, Arcturus reported a net income of approximately $117.3 million for Q4 2022, marking a significant improvement from the previous year's loss.

Arcturus Appoints John Markels, Ph.D. to its Board of Directors Dr. Markels, accomplished and experienced industry executive, most recently President of Global Vaccines at Merck, to provide strategic oversight to the Com

Appoints John Markels, Ph.D. to its Board of Directors accomplished and experienced industry executive, most recently President of Global Vaccines at Merck, to provide strategic oversight to the Company's vaccine franchise San Diego, Calif., December 13, 2022 - Arcturus Thera

Nov 9, 2022

▼ -7.6%on this news· ran to -20% by day 3

Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress Entered into global partnership with CSL to develop and commercialize self-amplifying mRNA vaccines targeting COVID-19, influenza,

Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress Entered into global partnership with CSL to develop and commercialize self-amplifying mRNA vaccines targeting COVID-19, influenza, additional pathogens, and pandemic preparedness with $2

Nov 1, 2022

Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines Arcturus to receive upfront payment of $200 million and more than $4 billion in potential development and commercial mi

Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines San Diego, Calif, November 1, 2022 - Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on t

Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response Arcturus will expand its current influenza vaccine program to i

Announces $63.2 Million Award from the U.S. Government to Support Development of mRNA Vaccine for Rapid Pandemic Influenza Response San Diego, California - Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global, late-stage clinical messenger R

Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress New ARCT-154 clinical booster data demonstrate promising durability; 44- and 39-fold increases in neutralizing antibody response

Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress New ARCT-154 clinical booster data demonstrate promising durability; 44- and 39-fold increases in neutralizing antibody response against Omicron BA.1 and BA.2 at Day 91 New cold chain d

May 9, 2022

▼ -11.3%on this news· ran to -21% by day 3

Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress ARCT-154 booster data show 54- and 46-fold increases in neutralizing antibody response against Omicron BA.1 and BA.2 Investor conf

Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress ARCT-154 booster data show 54- and 46-fold increases in neutralizing antibody response against Omicron BA.1 and BA.2 Investor conference call at 4:30 p.m. ET today SAN DIEGO-(BUSINESS WIRE)-May 9

Apr 20, 2022

Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study

Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study April 20, 2022 at 7:30 AM Efficacy overall for prevention of severe COVID-19 disease including related deaths Efficacy overall for preventing symptomatic COVID-1

Feb 28, 2022

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress Emergency Use Authorization (EUA) application for ARCT-154 submitted to Vietnam Ministry of Health ARCT-154 Phase 1

Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress Emergency Use Authorization (EUA) application for ARCT-154 submitted to Vietnam Ministry of Health ARCT-154 Phase 1/2 booster study data in U.S. and Singapore demonstrated 28-, and

Dec 13, 2021

Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors SAN DIEGO--(BUSINESS WIRE)

Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors SAN DIEGO--(BUSINESS WIRE)--Dec. 13, 2021-- Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the

Nov 8, 2021

Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress Phase 1/2/3a and 3b study of ARCT-154 COVID-19 vaccine candidate completed enrollment with over 17,000 participants Initiated ~2,0

Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress Phase 1/2/3a and 3b study of ARCT-154 COVID-19 vaccine candidate completed enrollment with over 17,000 participants Initiated ~2,000 participant ARCT-154 Phase 3c sub-study to compare i

Aug 9, 2021

Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress ARCT-021, Arcturus' single shot STARR mRNA COVID vaccine, to begin multinational placebo-controlle

Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress ARCT-021, Arcturus' single shot STARR mRNA COVID vaccine, to begin multinational placebo-controlled Phase 3 efficacy study funded and sponsored by a global entity A

May 10, 2021

Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data ARCT-021 Phase 2 interim data showed favorable safety profile and greater than 90% seroconversion a

Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical ARCT-021 Phase 2 interim data showed favorable safety profile and greater than 90% seroconversion after a single dose; data supports advancement into Phase 3 I

Mar 1, 2021

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates ARCT-021 single-shot COVID-19 STARR mRNA vaccine to be advanced to Phase 3 clinical development - on track

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates ARCT-021 single-shot COVID-19 STARR mRNA vaccine to be advanced to Phase 3 clinical development - on track to initiate Phase 3 study in Q2 ARCT-021 single shot

Feb 22, 2021

Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals SAN DIEGO--(BUSINESS WIRE)

Arcturus Therapeutics Acquires Exclusive to mRNA Manufacturing Technology from Alexion Pharmaceuticals SAN DIEGO--(BUSINESS WIRE)--Feb. 22, 2021-- Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines c

Dec 7, 2020

Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock SAN DIEGO, December 7, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the "Company", NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the d

Nov 9, 2020

Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data Investor conference call at 4:30 p.m. ET today San Diego,

Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data Investor conference call at 4:30 p.m. San Diego, Calif, Nov 9, 2020 - Arcturus Therapeutics Holdings Inc. (the

Sep 8, 2020

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

Arcturus Therapeutics Holdings Inc. announced its participation in upcoming virtual investor and scientific conferences. The company, based in San Diego, focuses on developing mRNA medicines and vaccines for infectious diseases and rare conditions. Its innovative technologies and diverse pipeline highlight its commitment to advancing RNA therapeutics.

Sep 4, 2020

Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate

Arcturus Therapeutics has announced promising preclinical results for its COVID-19 vaccine candidate, LUNAR®-COV19. The vaccine demonstrated a robust immune response and complete protection against SARS-CoV-2 in mice after a single dose. The company is currently advancing the vaccine into a Phase 1/2 clinical study, with initial data expected in Q4 2020.

Aug 18, 2020

Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health

Arcturus Therapeutics has finalized a supply agreement with the Israeli Ministry of Health for its COVID-19 STARR™ mRNA vaccine candidate, ARCT-021. This agreement follows a previously announced term sheet and is contingent on achieving clinical and regulatory milestones. Israel becomes the second country to reserve supply of this vaccine, highlighting its importance in the nation's vaccination efforts.

Aug 11, 2020

Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study

Arcturus Therapeutics has commenced dosing in its Phase 1/2 clinical study for the COVID-19 vaccine candidate ARCT-021. The study aims to evaluate the safety and immunogenicity of the vaccine, which has shown promising preclinical results. Initial clinical data is expected in Q4 2020, which will inform further dose selection for subsequent trials.

Aug 10, 2020

Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update

Arcturus Therapeutics reported its Q2 2020 financial results, highlighting the initiation of clinical studies for its COVID-19 vaccine candidate ARCT-021 and mRNA therapeutic ARCT-810. The company raised $280 million to support its clinical pipeline, despite a reported net loss of $10.3 million. Initial data from both clinical studies is expected in Q4 2020.

Aug 6, 2020

Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer

Arcturus Therapeutics has appointed Lance Kurata as Chief Legal Officer, effective August 10, 2020. Kurata, previously a partner at Mintz, brings extensive experience in biotechnology law. He expressed enthusiasm for joining Arcturus during a pivotal time, as the company expects clinical trial data for its COVID-19 vaccine and other investigational therapies.

Aug 4, 2020

Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020

SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within live

Jul 31, 2020

Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Arcturus Therapeutics announced the successful closing of its public offering, raising around $200 million. The offering included the full exercise of underwriters' options for additional shares. The funds will be allocated to the development of the LUNAR-COV19 vaccine and other RNA therapeutic programs. The company has a strong pipeline and collaborations with major pharmaceutical firms.

Jul 29, 2020

Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock

Arcturus Therapeutics has priced a public offering of 3,264,151 shares at $53.00 each, aiming to raise approximately $173 million. The proceeds will be used to further develop its LUNAR-COV19 vaccine candidate and other RNA therapeutic programs. The offering is set to close around July 31, 2020, pending customary conditions.

Jul 28, 2020

Arcturus Therapeutics Announces Proposed Public Offering of Common Stock

Arcturus Therapeutics announced a proposed public offering of its common stock to raise funds for the development of its LUNAR-COV19 vaccine and other RNA medicine projects. The offering will be managed by Citigroup, Guggenheim Securities, and Barclays. The company plans to use the proceeds for clinical development and general corporate purposes, although the completion of the offering is subject to market conditions.

Jul 23, 2020

Israel secures rights to stockpile and reserve doses of LUNAR-COV19 for its citizens Israel is the second country to reserve supply of LUNAR-COV19

Israel secures rights to stockpile and reserve doses of LUNAR-COV19 for its citizens Israel is the second country to reserve supply of LUNAR-COV19 SAN DIEGO, July 23, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a le

Jul 23, 2020

Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19

Jul 21, 2020

Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19

Human dosing of LUNAR-COV19 expected soon Differentiated STARR™ mRNA vaccine expected to produce humoral and cellular immunity at very low doses New preclinical data demonstrates neutralizing antibody titers continue to increase for 50 days after a single administration SAN DI

Jul 1, 2020

Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board

Renowned experts in virology, infectious disease, vaccine development and public health to support Arcturus’ COVID-19 vaccine program, LUNAR-COV19 Company remains on track to begin clinical trial for COVID-19 vaccine this summer SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Arct

Jun 29, 2020

Arcturus Therapeutics to be Added to Russell 2000 Index

SAN DIEGO, June 29, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and v

Jun 11, 2020

Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual Conference

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and v

Jun 5, 2020

Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency

SAN DIEGO, June 05, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and v

May 21, 2020

Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics NOVATO, Calif. and

Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics NOVATO, Calif. and SAN DIEGO, May 21, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical, Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercializa

May 8, 2020

Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)

New data provides evidence of adaptive cellular (CD8+ cells) and balanced (Th1/Th2) immune responses STARR™ mRNA elicits anti-spike protein antibodies (IgG), higher than conventional mRNA at all doses SAN DIEGO, May 08, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings In

May 7, 2020

Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update Important progress advancing COVID-19 STARR mRNA vaccine candidate (LUNAR-COV19); New preclinical data demonstrate robu

Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update Important progress advancing COVID-19 STARR mRNA vaccine candidate (LUNAR-COV19); New preclinical data demonstrate robust immunogenicity with a single, low dose Company rem

May 4, 2020

Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine

SAN DIEGO and SOMERSET, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus”, “the Company”, Nasdaq: ARCT), a leading clinical-stage messenger RNA (mRNA) medicines and vaccines company, and Catalent, Inc. (NYSE: CTLT), the leading global provider

May 4, 2020

Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020

SAN DIEGO, May 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and va

Apr 27, 2020

Arcturus Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate

100% of animals seroconverted by day 19 at a low dose (2 µg) LUNAR-COV19 remains on track to initiate human clinical trials this Summer SAN DIEGO, April 27, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinica

Apr 16, 2020

Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common Stock

SAN DIEGO, April 16, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, to

Apr 13, 2020

Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase Deficiency

Clinical Plan Includes Healthy Volunteers in New Zealand and OTC-Deficient Patients Across Several Sites in United States Investor Conference Call at 4:00 pm ET Today SAN DIEGO, April 13, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading cl

Apr 9, 2020

Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine

GMP-Manufactured Batch to be Delivered in June 2020 Human Dosing Expected to Begin in Summer 2020 SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development a

Mar 27, 2020

Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System

SAN DIEGO, March 27, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines and vaccines company, today provided details about the Company’s strategy to rapidly learn about the safety and efficacy profile of its COVID-19 va

Mar 11, 2020

Arcturus Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results IND Filed for Flagship Program ARCT-810 Coronavirus Vaccine Program Initiated Investor Conference Call at 4:30 pm ET Today San Diego, Calif

Arcturus Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results IND Filed for Flagship Program ARCT-810 Coronavirus Vaccine Program Initiated Investor Conference Call at 4:30 pm ET San Diego, Calif, March 11, 2020 - Arcturus Therapeutics (the "Company", NAS

Mar 4, 2020

Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR TechnologyTM Collaboration seeks to conduct pre-clinical testing followed by first-in-human clinical trial

Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR TechnologyTM seeks to conduct pre-clinical testing followed by first-in-human clinical trials San Diego, Calif, USA and Singapore, March 4, 2020 - Arcturus Thera

Feb 24, 2020

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2019 Financial Results and Provide Corporate Update on March 11

SAN DIEGO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it will provide a corpor

Feb 19, 2020

Arcturus Therapeutics to Present at Two Investor Conferences in March

SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Joseph Payne, Chief Exec

Jan 8, 2020

Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development Officer

SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced the appointment of Steve Hugh

Nov 7, 2019

Arcturus Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update San Diego, Calif

Arcturus Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update San Diego, Calif, November 7, 2019 Arcturus Therapeutics Holdings Inc. ( Arcturus Therapeutics ) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, dev

Nov 7, 2019

FORWARD LOOKING STATEMENTS ARCTURUS THERAPEUTICS This presentation contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which

Building the Next Generation of RNA Medicines ARCTURUS THERAPEUTICS November 2019 Exhibit 99.1 FORWARD LOOKING STATEMENTS ARCTURUS THERAPEUTICS This presentation contains forward-looking statements. These statements relate to future events and involve known and unknown risks,

Nov 7, 2019

Arcturus Therapeutics Expands Platform with STARR Technology™

SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (NASDAQ: ARCT, the “Company”), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that the Company is expanding

Nov 4, 2019

Arcturus Therapeutics to Report Corporate Overview and Financial Results on November 7th

SAN DIEGO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it will provide a corporate overview an

Oct 2, 2019

Arcturus Therapeutics to Present at Three Upcoming Investor Conferences

SAN DIEGO, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that

Sep 26, 2019

Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock San Diego, Calif

Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock San Diego, Calif, September 26, 2019 Arcturus Therapeutics ( Arcturus or the Company ), a leading RNA medicines company focused on the discovery, development and commercialization of mRNA th

Sep 23, 2019

Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. and Re-Appointment of Andy Sassine to the Board of Directors San Diego, Calif

Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. and Re-Appointment of Andy Sassine to the Board of Directors San Diego, Calif, September 23, 2019 Arcturus Therapeutics Holdings Inc. ( Arcturus Therapeutics ) (NASDAQ: ARCT), a leading messenger RNA medicin

Aug 26, 2019

Arcturus Therapeutics To Present at Two Investor Conferences in September

SAN DIEGO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that

Aug 15, 2019

Arcturus Therapeutics Announces Second Quarter Financial Results and Provides a Corporate Update Ultragenyx Pharmaceutical, Inc. expands collaboration, becoming Arcturus largest shareholder Cystic Fibrosis Foundation inc

Arcturus Therapeutics Announces Second Quarter Financial Results and Provides a Corporate Update San Diego, Calif, August 15, 2019 Arcturus Therapeutics Holdings Inc. ( Arcturus Therapeutics ) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, d

Aug 7, 2019

Arcturus to Report Corporate Overview and Financial Results on August 15

SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it will provide a corpo

Aug 2, 2019

Arcturus Therapeutics Announces $2.3 Million Additional Registered Direct Offering of Common Stock San Diego, Calif

Arcturus Therapeutics Announces $2.3 Million Additional Registered Direct Offering of Common Stock San Diego, Calif, August 2, 2019 Arcturus Therapeutics ( Arcturus or the Company ), a leading RNA medicines company focused on the discovery, development and commercialization of

Aug 1, 2019

Arcturus Therapeutics Announces $10.9 Million Registered Direct Offering of Common Stock San Diego, Calif

Arcturus Therapeutics Announces $10.9 Million Registered Direct Offering of Common Stock San Diego, Calif, August 1, 2019 Arcturus Therapeutics ( Arcturus or the Company ), a leading RNA medicines company focused on the discovery, development and commercialization of therapeuti

Aug 1, 2019

Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis Foundation to Create mRNA Therapies to Treat Cystic Fibrosis Patients San Diego, Calif

Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis Foundation to Create mRNA Therapies to Treat Cystic Fibrosis Patients San Diego, Calif, August 1, 2019 - Arcturus Therapeutics ("Arcturus" or the "Company"), a leading RNA medicines company, t

Jul 10, 2019

Arcturus Therapeutics to Participate in Two Panels at the ROTH RNA Revolution Conference

SAN DIEGO, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Joseph Payne, P

Jun 27, 2019

Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-810, for Treatment of Ornithine Transcarbamylase (OTC) Deficiency

SAN DIEGO, June 27, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, liver and respiratory diseases with significant unmet medical need, toda

Jun 19, 2019

Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases Scope of the collaboration expands to include up to 12 rare

Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases NOVATO, Calif., and SAN DIEGO, Calif., June 19, 2019 Ultragenyx Pharmaceutical, Inc. (Nasdaq: RARE), a biopharmaceuti

Jun 13, 2019

Arcturus Therapeutics Announces Redomiciliation to the United States as a Delaware Corporation

SAN DIEGO, June 13, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it has ob

Jul 20, 2018

Arcturus Therapeutics Announces Annual and Extraordinary General Meeting of Shareholders to Be Held on August 24, 2018

SAN DIEGO, July 20, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (“Arcturus” or the “Company”) (NASDAQ:ARCT), an RNA medicines company, today announced that it will hold an Annual and Extraordinary General Meeting of Shareholders (or the “Meeting”), on Friday, August 24, 2

May 31, 2018

Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders

SAN DIEGO, May 30, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (“Arcturus” or the “Company”) (NASDAQ:ARCT), an RNA medicines company, today announced that the Extraordinary General Meeting of the Shareholders of the Company that was announced on May 21, 2018 and was sched

May 31, 2018

Arcturus Announces Management Appointments; Company Founder Joseph E. Payne Reinstated as President and CEO

Industry veteran Dr. Peter Farrell named as Chairman of the Board, Dr. Pad Chivukula reinstated as CSO and COO SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today announced that Dr. Peter Farrell has been n

May 29, 2018

Arcturus Therapeutics Appoints Four New Directors and Reaches Settlement Agreement with Founder Joseph E. Payne

SAN DIEGO, May 29, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT) (“Arcturus” or the “Company), a leading RNA medicines company, today announced that, as part of a settlement agreement, it has appointed four new independent directors, Dr. Peter Farrell, Mr. And

May 23, 2018

Arcturus Therapeutics Founder Joseph Payne Calls for an End to Company’s Frivolous and Costly Lawsuits; Applauds Court Decision and Welcomes June 25, 2018 EGM Date

Applauds court decision to require disclosure of complaint filed against Joe Payne and other Arcturus shareholders as reasonable solution to end costly securities litigation Welcomes Israeli Court order that forced Arcturus Board to set date for Extraordinary General Meeting (“E

May 14, 2018

Arcturus Therapeutics Files Form 20-F

SAN DIEGO, May 14, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today announced the filing of the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2017 with the U.S. Securities and Exchange Commissi

May 14, 2018

Arcturus Therapeutics Founder Joseph Payne Welcomes Court Decision to Set Date and Agenda of Extraordinary General Meeting to Vote for New Board Members

Court rules that a notification for Extraordinary General Meeting must be issued this week The Extraordinary General Meeting to be scheduled between June 18 and June 24, 2018 Court ruling also establishes an agenda for the June meeting that is substantially identical to the age

May 2, 2018

Arcturus Therapeutics Founder Joseph Payne Successfully Prevents Board’s Egregious Attempt to Dilute Shareholders

Israeli District Court enjoins attempt by board to dilute shareholders through sale of 24.9% of Arcturus share capital Court found sufficient evidence to support the claim that the members of the Arcturus board are motivated by their own self-interests instead of the interests o

Apr 23, 2018

Arcturus Therapeutics Founder Joseph Payne Dismisses Board’s Baseless Lawsuit as Desperate Entrenchment Tactic

Warns lawsuit is another attempt by Arcturus’ board to distract shareholders from the Company’s abhorrent governance deficiencies Calls on board to respect the rights of all shareholders and immediately set date for Extraordinary General Meeting SAN DIEGO, April 23, 2018 (GLOBE

Apr 20, 2018

Arcturus Therapeutics Files Lawsuit Against Joseph E. Payne and His Associates for Violations of Federal Securities Laws

Complaint Details Multiple Violations of Federal Securities Laws by Undisclosed Group Led by Payne SAN DIEGO, April 20, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, initiated a lawsuit in the United States District Court for

Apr 13, 2018

Arcturus Therapeutics Founder Joseph Payne Disappointed by Board’s Desperate Attempt to Delay Meeting and Avoid Shareholder Accountability

Change in Arcturus board is needed on an urgent basis to improve the company’s performance Board’s decision to indefinitely delay inevitable change is a clear act of entrenchment Overwhelming support for Mr. Payne’s nominees indicates change is mandated, positive, and inevitabl

Apr 8, 2018

Arcturus Therapeutics Issues Statement Regarding Timing of Extraordinary General Meeting of Shareholders

Postponement due to Joseph Payne’s Focus on Advancing His Personal Agenda at the Expense of Arcturus Shareholders SAN DIEGO, April 08, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today announced that upon the recommendation

Mar 28, 2018